Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0016020 | membrane | 2 | 11 |
GO:0110165 | cellular anatomical entity | 1 | 11 |
GO:0005739 | mitochondrion | 5 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043227 | membrane-bounded organelle | 3 | 1 |
GO:0043229 | intracellular organelle | 3 | 1 |
GO:0043231 | intracellular membrane-bounded organelle | 4 | 1 |
Related structures:
AlphaFold database: A4HGK8
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_MEL_PAP_1 | 64 | 70 | PF00089 | 0.633 |
CLV_NRD_NRD_1 | 148 | 150 | PF00675 | 0.408 |
CLV_NRD_NRD_1 | 166 | 168 | PF00675 | 0.220 |
CLV_NRD_NRD_1 | 189 | 191 | PF00675 | 0.341 |
CLV_NRD_NRD_1 | 97 | 99 | PF00675 | 0.341 |
CLV_PCSK_KEX2_1 | 148 | 150 | PF00082 | 0.408 |
CLV_PCSK_KEX2_1 | 166 | 168 | PF00082 | 0.220 |
CLV_PCSK_KEX2_1 | 97 | 99 | PF00082 | 0.341 |
DEG_APCC_DBOX_1 | 66 | 74 | PF00400 | 0.345 |
DEG_Nend_UBRbox_2 | 1 | 3 | PF02207 | 0.722 |
DOC_MAPK_gen_1 | 164 | 174 | PF00069 | 0.530 |
DOC_MAPK_MEF2A_6 | 166 | 174 | PF00069 | 0.647 |
DOC_MAPK_NFAT4_5 | 167 | 175 | PF00069 | 0.612 |
DOC_PP1_RVXF_1 | 73 | 79 | PF00149 | 0.277 |
DOC_PP4_FxxP_1 | 142 | 145 | PF00568 | 0.607 |
DOC_PP4_FxxP_1 | 31 | 34 | PF00568 | 0.620 |
DOC_PP4_FxxP_1 | 5 | 8 | PF00568 | 0.551 |
LIG_14-3-3_CanoR_1 | 67 | 71 | PF00244 | 0.364 |
LIG_APCC_ABBA_1 | 208 | 213 | PF00400 | 0.623 |
LIG_BRCT_BRCA1_1 | 192 | 196 | PF00533 | 0.618 |
LIG_eIF4E_1 | 155 | 161 | PF01652 | 0.589 |
LIG_FHA_1 | 192 | 198 | PF00498 | 0.594 |
LIG_FHA_1 | 219 | 225 | PF00498 | 0.566 |
LIG_FHA_1 | 49 | 55 | PF00498 | 0.340 |
LIG_FHA_1 | 88 | 94 | PF00498 | 0.339 |
LIG_LIR_Apic_2 | 139 | 145 | PF02991 | 0.616 |
LIG_LIR_Apic_2 | 2 | 8 | PF02991 | 0.640 |
LIG_LIR_Apic_2 | 29 | 34 | PF02991 | 0.638 |
LIG_LIR_Gen_1 | 48 | 57 | PF02991 | 0.441 |
LIG_LIR_LC3C_4 | 51 | 54 | PF02991 | 0.210 |
LIG_LIR_Nem_3 | 130 | 136 | PF02991 | 0.576 |
LIG_LIR_Nem_3 | 200 | 206 | PF02991 | 0.524 |
LIG_LIR_Nem_3 | 230 | 236 | PF02991 | 0.585 |
LIG_LIR_Nem_3 | 48 | 52 | PF02991 | 0.441 |
LIG_NRBOX | 156 | 162 | PF00104 | 0.584 |
LIG_NRBOX | 167 | 173 | PF00104 | 0.530 |
LIG_Pex14_2 | 78 | 82 | PF04695 | 0.302 |
LIG_REV1ctd_RIR_1 | 56 | 64 | PF16727 | 0.464 |
LIG_SH2_CRK | 203 | 207 | PF00017 | 0.607 |
LIG_SH2_CRK | 233 | 237 | PF00017 | 0.561 |
LIG_SH2_CRK | 41 | 45 | PF00017 | 0.393 |
LIG_SH2_NCK_1 | 41 | 45 | PF00017 | 0.362 |
LIG_SH2_PTP2 | 62 | 65 | PF00017 | 0.398 |
LIG_SH2_STAP1 | 19 | 23 | PF00017 | 0.693 |
LIG_SH2_STAP1 | 41 | 45 | PF00017 | 0.426 |
LIG_SH2_STAP1 | 89 | 93 | PF00017 | 0.318 |
LIG_SH2_STAT5 | 56 | 59 | PF00017 | 0.376 |
LIG_SH2_STAT5 | 62 | 65 | PF00017 | 0.373 |
LIG_SH2_STAT5 | 89 | 92 | PF00017 | 0.328 |
LIG_SUMO_SIM_anti_2 | 110 | 115 | PF11976 | 0.534 |
LIG_SUMO_SIM_anti_2 | 220 | 226 | PF11976 | 0.578 |
LIG_SUMO_SIM_anti_2 | 51 | 56 | PF11976 | 0.210 |
LIG_SUMO_SIM_par_1 | 88 | 94 | PF11976 | 0.418 |
LIG_TYR_ITIM | 231 | 236 | PF00017 | 0.544 |
LIG_TYR_ITIM | 39 | 44 | PF00017 | 0.393 |
LIG_UBA3_1 | 160 | 164 | PF00899 | 0.576 |
LIG_UBA3_1 | 170 | 175 | PF00899 | 0.531 |
LIG_UBA3_1 | 222 | 227 | PF00899 | 0.645 |
MOD_CK1_1 | 66 | 72 | PF00069 | 0.360 |
MOD_CK2_1 | 176 | 182 | PF00069 | 0.640 |
MOD_GlcNHglycan | 151 | 154 | PF01048 | 0.412 |
MOD_GlcNHglycan | 178 | 181 | PF01048 | 0.441 |
MOD_GlcNHglycan | 20 | 24 | PF01048 | 0.478 |
MOD_GlcNHglycan | 26 | 29 | PF01048 | 0.422 |
MOD_GlcNHglycan | 79 | 82 | PF01048 | 0.337 |
MOD_GSK3_1 | 123 | 130 | PF00069 | 0.581 |
MOD_GSK3_1 | 132 | 139 | PF00069 | 0.609 |
MOD_GSK3_1 | 151 | 158 | PF00069 | 0.484 |
MOD_GSK3_1 | 191 | 198 | PF00069 | 0.576 |
MOD_GSK3_1 | 202 | 209 | PF00069 | 0.493 |
MOD_GSK3_1 | 87 | 94 | PF00069 | 0.440 |
MOD_N-GLC_1 | 107 | 112 | PF02516 | 0.317 |
MOD_N-GLC_1 | 136 | 141 | PF02516 | 0.478 |
MOD_NEK2_1 | 170 | 175 | PF00069 | 0.615 |
MOD_NEK2_1 | 196 | 201 | PF00069 | 0.574 |
MOD_NEK2_1 | 206 | 211 | PF00069 | 0.506 |
MOD_NEK2_2 | 26 | 31 | PF00069 | 0.563 |
MOD_PK_1 | 204 | 210 | PF00069 | 0.607 |
MOD_PKA_1 | 190 | 196 | PF00069 | 0.570 |
MOD_PKA_2 | 66 | 72 | PF00069 | 0.361 |
MOD_PKB_1 | 149 | 157 | PF00069 | 0.586 |
MOD_Plk_1 | 107 | 113 | PF00069 | 0.518 |
MOD_Plk_4 | 102 | 108 | PF00069 | 0.566 |
MOD_Plk_4 | 218 | 224 | PF00069 | 0.596 |
MOD_Plk_4 | 26 | 32 | PF00069 | 0.567 |
MOD_Plk_4 | 48 | 54 | PF00069 | 0.350 |
MOD_Plk_4 | 91 | 97 | PF00069 | 0.410 |
MOD_SUMO_rev_2 | 207 | 217 | PF00179 | 0.656 |
TRG_DiLeu_BaEn_1 | 156 | 161 | PF01217 | 0.588 |
TRG_DiLeu_BaEn_1 | 220 | 225 | PF01217 | 0.619 |
TRG_DiLeu_BaEn_2 | 191 | 197 | PF01217 | 0.563 |
TRG_ENDOCYTIC_2 | 203 | 206 | PF00928 | 0.608 |
TRG_ENDOCYTIC_2 | 233 | 236 | PF00928 | 0.617 |
TRG_ENDOCYTIC_2 | 41 | 44 | PF00928 | 0.381 |
TRG_ENDOCYTIC_2 | 56 | 59 | PF00928 | 0.272 |
TRG_ENDOCYTIC_2 | 62 | 65 | PF00928 | 0.328 |
TRG_ER_diArg_1 | 147 | 149 | PF00400 | 0.613 |
TRG_ER_diArg_1 | 166 | 168 | PF00400 | 0.578 |
TRG_ER_diArg_1 | 96 | 98 | PF00400 | 0.544 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N0P3N3 | Leptomonas seymouri | 79% | 82% |
A0A0S4J943 | Bodo saltans | 55% | 76% |
A0A1X0NYS0 | Trypanosomatidae | 61% | 86% |
A0A3Q8IB08 | Leishmania donovani | 93% | 100% |
A0A3R7KJ52 | Trypanosoma rangeli | 65% | 85% |
A4I3N4 | Leishmania infantum | 93% | 100% |
D0A864 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 59% | 86% |
E9AZX5 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 92% | 100% |
Q4Q8B0 | Leishmania major | 92% | 100% |
V5ASF1 | Trypanosoma cruzi | 65% | 85% |